DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+CD15− cells in early chronic‐phase chronic myeloid leukemia
Despite the high efficiency of tyrosine kinase inhibitors (TKI), some patients with chronic myeloid leukemia (CML) will display residual disease that can become resistant to treatment, indicating intraclonal heterogeneity in chronic‐phase CML (CP‐CML). To determine the basis of this heterogeneity, w...
Main Authors: | Stéphanie Maupetit‐Mehouas, Franck Court, Céline Bourgne, Agnès Guerci‐Bresler, Pascale Cony‐Makhoul, Hyacinthe Johnson, Gabriel Etienne, Philippe Rousselot, Denis Guyotat, Alexandre Janel, Eric Hermet, Sandrine Saugues, Juliette Berger, Philippe Arnaud, Marc G. Berger |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-06-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12191 |
Similar Items
-
Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients
by: Henrike Jacobi, et al.
Published: (2023-07-01) -
CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26)
by: Ji-Hea Kim, et al.
Published: (2023-11-01) -
Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response
by: Rebecca Warfvinge, et al.
Published: (2024-11-01) -
Predicting drug resistance
by: Nicole S Arellano, et al.
Published: (2024-11-01) -
ENOX2 NADH Oxidase: A BCR-ABL1-Dependent Cell Surface and Secreted Redox Protein in Chronic Myeloid Leukemia
by: Seda Baykal, et al.
Published: (2023-06-01)